Reply: To PMID 23873583.


genotype was significantly associated with treatment response in each arm of the trial (P5 0.04, Fisher’s exact test; Fig. 1). It appears, therefore, that a very high proportion of patients with a favorable host genotype who meet the selection criteria for this trial will achieve SVR with 24 weeks of peg-interferon-a/ribavirin alone. Otherwise similar… (More)
DOI: 10.1002/hep.26777


Cite this paper

@article{Pearlman2014ReplyTP, title={Reply: To PMID 23873583.}, author={Brian L. Pearlman and Carole M Ehleben}, journal={Hepatology}, year={2014}, volume={59 6}, pages={2424} }